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ABSTRACT
Objective: The main aim of this study is to compare the effectiveness of treatment of osteoarthritis (OA) with hydroxychloroquine against diclofenac 
and to compare the safety of the treatment of OA with hydroxychloroquine against diclofenac. The secondary objectives are the comparison of onset 
and duration of action of both the treatments.
Methods: A prospective interventional study has been done in a tertiary care teaching hospital for 1 year from January 2016 to December 2016. The 
interventional model included an active control (diclofenac - nonsteroidal anti-inflammatory drugs). The control group received diclofenac 75 mg for 
12 weeks, whereas the test group received hydroxychloroquine 200 mg for 3 months.
Results: Pain control is significantly rapid in diclofenac group, whereas the duration of action is significantly increased in hydroxychloroquine. It can 
be clearly seen that the hydroxychloroquine group significantly increases the quality of life when compared to diclofenac group. It is clearly seen that 
the incidence of gastric ulcers is more common in diclofenac group when compared to hydroxychloroquine group.
Conclusion: Hydroxychloroquine offers a newer spectrum in the management of OA. Although it is slow acting, it has significantly increased the 
quality of patient as it can have a prolonged action. Hence, hydroxychloroquine can be used as a newer entity in the management of OA.
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INTRODUCTION
Osteoarthritis (OA) is the most widespread type among arthritis, 
triggering a considerable joint aches and fragility. OA is one of the chief 
reasons of health-care outflow, and its occurrence will further upsurge 
with the old-age people. Existing treatments for OA have significant 
restrictions and novel analgesic therapies are required. Synovitis is 
predominant in OA and is usually accompanied with pain. For treating 
synovitis in inflammatory arthritis, the hydroxychloroquines are used [1].
Hydroxychloroquine is an aminoquinolone primarily an antimalarial 
drug. It inhibits movement of neutrophils and chemotaxis of eosinophils 
and damages complement-associated antigen-antibody reactions [2,3].
Nonsteroidal anti-inflammatory drugs (NSAIDs) are enzyme inhibitors. 
They block cyclooxygenase (COX-1 and COX-2 enzymes), which is liable 
for the production of prostaglandins and thromboxane [4,5].
Aim
The main aim is to compare the effectiveness of treatment of OA with 
hydroxychloroquine against diclofenac and to compare the safety of 
treatment of OA with hydroxychloroquine against diclofenac. The 
secondary objectives are the comparison of onset and duration of 
action of both the treatments.
METHODS
Sample size
Sample size was estimated with a prevalence of 100 patients. The 
estimated sample size with a confidence interval of 95% was found to 
be 80 with a 2.75% margin of error.
Study design
A prospective interventional study has been carried out in a tertiary 
care hospital for 1 year from January 2017 to December 2017. The 
interventional model included an active control (diclofenac - NSAIDs).
Patient selection
Inclusion criteria






The following criteria were excluded from the study:
•	 Pregnant	and	nursing	women.
•	 People	diagnosed	with	multiple	inflammation.




An informed consent has been obtained from all the included patients. 
Patients’ confidentiality has been maintained throughout this study. 
The work has been approved by the Institutional Ethics Committee 
IEC/VELS/DOPV/2016/33.
A specially designed pro forma has been utilized to carry out this study. 
Patients demographics such as age, sex, laboratory values, patient medical 
history etc were collected. The patient was followed up for every month. 
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The control group received diclofenac 75 mg for 12 weeks, whereas the 
test group received hydroxychloroquine 200 mg BD for 3 months. Patients’ 
quality of life is measured before the initiation of the study as well as 
the conclusion of 3 months. Standard validated SF-12 questionnaire is 
administered before and after the end of intervention. Physical and mental 
component scoring was assessed. Laboratory data such as erythrocyte 
sedimentation rate were estimated to compare the efficacy.
Statistical analysis
One sample student t-test was used to compare the quality of life among 
the patients. Chi-squared test was used to compare the control of 95% 
and a p<0.05 is considered to be statistically significant.
RESULTS
The following results were obtained in the study.
Table 1 shows that female are more prone to OA when compared to 
male distribution.
Table 2 shows that patients between 50 and 65 years of age are more 
prone to OA when compared to other age distribution.
Table 3 shows that knee OA patients are more prone when compared 
to other types.
Table 4 shows that diabetes mellitus (DM) patients are more prone to 
OA when compared to other comorbidities (Tables 5-8).
Pain control is significantly rapid in diclofenac group, whereas the 
duration of action is significantly increased in hydroxychloroquine.
It can be clearly seen that the hydroxychloroquine group significantly 
increases the quality of life when compared to diclofenac group.
It is clearly seen that the incidence of gastric ulcers is more common in 
diclofenac group when compared to hydroxychloroquine group.
DISCUSSION
In general, women are more prone to the OA when compared to the 
men. Specialist’s assessment is that almost 60% of the women in the US 
are having OA. Similar patterns were reported in our study.
The anatomy of a female’s physique is organized in such a way which 
may show a part in her risk for OA of the knees. Specifically, woman 
tends to have broader hips, in which some specialists’ belief affects the 
position of the knee and causes irregular stress on the knees, leading 
to OA [6].
As age increases, the highest risk factor for OA is also increases, and it 
is not an unavoidable magnitude of getting aged. The elderly changes 
in joint tissues that fund to the growth of OA include cell senescence 
that fallouts in the expansion of the senescent secretory phenotype and 
aging variations in the matrix, including the development of progressive 
glycation end products that affect the mechanical possessions of joint 
tissues [7,8].
Knee OA is of additional importance not only for its significant 
occurrence rate related with other forms of OA but also for its 
appearance at earlier age groups predominantly in younger age groups 
of overweight women. The incidence of knee OA increases by age and 
further increases with lengthier lifetime and advanced usual weight of 
the population [9].
DM and hyperglycemia are correlated with OA in some epidemiological 
studies. Moreover, the relationship within the two diseases might be 
supported by the lethal role of glucose spare through the buildup of 
advanced glycation end products, oxidative stress, and promotion of 
systemic inflammation [10,11].
Hydroxychloroquine blocks the action of certain chemical messengers 
that are responsible for inflammation, swelling, and redness associated 
with certain joint diseases. Although it is slow acting, duration of the 
action of hydroxychloroquine is more when compared to diclofenac 
(NSAIDs).
Diclofenac spreads into and out of the synovial fluid. Dispersal into the 
joints happens when plasma levels are upper than those in the synovial 
fluid, after which the progression reverses and synovial fluid levels are 
Table 1: Gender distribution
Gender Number of patients (%)
Male 16 (25)
Female 64 (75)
Table 2: Age distribution
Age group (n=80) Number of patients (%)
18–35 years 8 (10)
35–50 years 20 (25)
50–65 years 36 (45)
>65 years 16 (20)
Table 3: OA type











No comorbidities 12 (15.00)
DM: Diabetes mellitus
Table 5: Test characteristics
Characteristics Group A (n=40) diclofenac (%) Group B (n=40) hydroxychloroquine (%) p values
Age (mean±SEM) 51.66±2.17 50.27±1.36 0.1726
Female (n=64) 35 29 0.3428
Alcoholic 3 (3.75) 4 (5.00) 0.2217
Smoker 1 (1.25) 0 (0.00) 0.2916
ESR (mean±SEM) (before treatment) 37.6±4.12 35.8±2.76 0.2317
Pain control time 1.24±0.6 h 3.12±2.24 h 0.0496*
Time taken for remission of pain 2.56±0.3 h 7.44±1.16 h 0.0047*
*p<0.05 is considered significant at 95% confidence interval
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higher than plasma levels. It is not known whether diffusion into the 
joint plays a role in the efficiency of diclofenac. However, it shows rapid 
onset of action when compared to hydroxychloroquine.
Gastric acid plays a tolerant role both in Helicobacter pylori and NSAID-
induced ulcers. Thus proton-pump inhibitors are useful for primary 
and secondary ulcer prevention [12].
CONCLUSION
Hydroxychloroquine offers a newer spectrum in the management of OA. 
Although it is slow acting, it has significantly increased the quality of 
patient as it can have a prolonged action. Hence, hydroxychloroquine 
can be used as a newer entity in the management of OA.
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Table 8: ADR reported in the study
ADR Group A (n=40) Group B (n=40) p value
GI ulcers 12 (15.00) 2 (2.50) 0.0327
Nausea/vomiting 7 (8.75) 4 (5.00) 0.0926
Tinnitus 0 4 (5.00) 0.0927
Leucopenia 3 (3.75) 9 (11.25) 0.2716
ADR: Adverse drug reactions, GI: Gastric. p<0.05 is considered to be statistically 
significant at 95% confidence interval
Table 6: PCS and MCS 
Groups Group A Group B p valuea
Before After (a) p value Before After (a) p value
PCS 36.12+2.17 44.72+1.26 0.0927 36.82+1.17 54.17+2.26 0.0236* 0.0436*
MCS 31.16+2.47 39.16+0.97 0.0628 31.29+1.62 51.17+1.12 0.0059* 0.0061*
aComparison of after treatment of Group A and Group B, *p<0.05 is considered significant, PCS: Physical component score, MCS: Mental component score
Table 7: Treatment efficacy after 3 months depending on SF‑12
Groups Number of patients with improvement Number of patients without improvement Total
Group A 28 12 40
Group B 35* 5 40
Total 6.3 17 80
On performing χ2, Group B value was found to be 12.167 and p value was found to be 0.0396. p<0.05 is considered to be statistically significant at 95% confidence 
interval
